The St. Louis-based payer slipped into the red during the second quarter for the first time since 2022. Centene executives said they were disappointed and frustrated by the results.
Centene stock hits decade low after insurer reports rare loss on higher medical costs Read More »
Las arañas y los escorpiones existen desde hace unos 400 millones de años y han experimentado pocos cambios evolutivos. Junto con otros artrópodos estrechamente relacionados, agrupados en la clase taxonómica de los arácnidos, han venido siendo uno de los grupos de …
Inesperado origen oceánico de las arañas y los escorpiones Read More »
Los aviones supersónicos generan al cruzar la barrera del sonido una serie de ondas de choque que se fusionan generando un gran estruendo. Los aviones supersónicos arrastran estos sonidos increíblemente fuertes a lo largo de su trayectoria de vuelo, creando niveles de ruido que …
Prueban en la pista el avión supersónico silencioso X-59 Read More »
The collaboration focuses on ‘molecular gates,’ a class of molecules that the startup company Gate Bioscience says can stop pathogenic proteins from leaving the cell.
Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines Read More »
While the plan rarely mentions healthcare, it is one of the administration’s first steps to set federal policies, which experts say is important to safely deploy the technology in the sector.
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne muscular dystrophy.
Sarepta Fallout Continues with EU’s Negative Opinion of Elevidys in Ambulatory Patients Read More »
Unos científicos han realizado experimentos de laboratorio para resolver el misterio sobre el origen del peróxido de hidrógeno (H₂O₂) en Europa, una de las lunas del planeta Júpiter. Los resultados de estos experimentos ayudan a explicar las desconcertantes observacio …
The technology, called CARE, is expected to allow for faster development of AI models that can cover more health conditions.
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an anonymous senior FDA official. Given Elevidys’ full approval, however, experts told BioSpace this path would set up a length legal battle between the regulator and Sarepta Therapeutics.
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys Read More »
The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for an investigational gene therapy and an FDA rejection for its lead asset.
Rocket Trims Headcount and Pipeline Focus Amid Clinical, Regulatory Turbulence Read More »
